

Connecting patients with the treatments that work for them?

LEARN MORE >



Advances in biomarker testing can make the difference

LEARN MORE >



Are you thinking beyond *BRCA*?

FIND OUT MORE

©2021 AstraZeneca.
All rights reserved.
US-52862
Last Updated 6/21

View footnotes/references



~1 in 2 patients with advanced ovarian cancer are HRD-positive¹

FIND OUT MORE



~1 in 2 patients with advanced ovarian cancer are HRD-positive¹

FIND OUT MORE

©2021 AstraZeneca.
All rights reserved.
US-52862

View footnotes/references

REFERENCES: 1Lord CJ, Ashworth A. Nature. 2012;481(7381):287-294.



Tissue is only part of the picture in metastatic NSCLC

EXPLORE NOW



EGFR and biomarker testing

EXPLORE NOW



Work with your team to integrate liquid biopsy testing

EXPLORE NOW